Baxalta, Inc. now part of Shire
Researcb, option and license agreement
In January 2016, Symphogen announced an exclusive research, option, and license agreement with Baxalta Incorporated and Baxalta GmbH, which have since been acquired by Shire, and granted Shire an option to obtain, upon the achievement of certain development milestones, an exclusive, worldwide license under Symphogen's technology to develop, make, and commercialize antibody monotherapies directed at certain agreed oncology targets and pharmaceutical products containing those antibodies.
The Shire Agreement covers three pre-agreed targets, and provides Shire with the option to include additional three targets. Under the agreement, Symphogen received an upfront payment of DKK 1.2 billion. The aggregated potential deal value of the collaboration is DKK 11 billion plus royalties on worldwide sales.
Collaboration and licence agreement
In 2008, Symphogen entered a strategic collaboration with Genentech for the development of antibody therapeutics against undisclosed infectious disease targets. Under the terms of the agreement, Genentech made an upfront payment to Symphogen as well as an equity investment in Symphogen. Symphogen is eligible for milestone payments exceeding DKK 700 million upon the successful achievement of certain research and development milestones, as well as royalties on worldwide sales. Genentech is currently in Phase 1 trials with an infectious disease mAb developed under the collaboration.